A choice of shot or infusion for Ocrevus users
A 10-minute injection or a two-hour infusion? Which would you prefer to treat your multiple sclerosis (MS)? That choice is now available, following the U.S. Food and Drug Administration’s approval of Ocrevus Zunovo in mid-September. The treatment combines Genentech’s very popular Ocrevus with ocrelizumab with a drug delivery system called Enhanze. Ocrevus, according to Genentech, has been used to treat more than 350,000 people with MS (PwMS) since it was…Continue Reading